384 related articles for article (PubMed ID: 24893124)
1. Development of synthetic lethality anticancer therapeutics.
Fang B
J Med Chem; 2014 Oct; 57(19):7859-73. PubMed ID: 24893124
[TBL] [Abstract][Full Text] [Related]
2. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethality-based targets for discovery of new cancer therapeutics.
Weidle UH; Maisel D; Eick D
Cancer Genomics Proteomics; 2011; 8(4):159-71. PubMed ID: 21737609
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.
Soncini D; Caffa I; Patrone F; Ballestrero A; Nencioni A
Curr Cancer Drug Targets; 2012 May; 12(4):329-38. PubMed ID: 22385509
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
[TBL] [Abstract][Full Text] [Related]
7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
8. Embracing synthetic lethality of novel anticancer therapies.
Kamal A; Shaik TB; Malik MS
Expert Opin Drug Discov; 2015 Oct; 10(10):1119-32. PubMed ID: 26211783
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
11. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
[TBL] [Abstract][Full Text] [Related]
12. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
13. Applying synthetic lethality for the selective targeting of cancer.
McLornan DP; List A; Mufti GJ
N Engl J Med; 2014 Oct; 371(18):1725-35. PubMed ID: 25354106
[No Abstract] [Full Text] [Related]
14. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Pessetto ZY; Yan Y; Bessho T; Natarajan A
Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality to overcome cancer drug resistance.
Porcelli L; Quatrale AE; Mantuano P; Silvestris N; Brunetti AE; Calvert H; Paradiso A; Azzariti A
Curr Med Chem; 2012; 19(23):3858-73. PubMed ID: 22788762
[TBL] [Abstract][Full Text] [Related]
19. DNA repair and synthetic lethality.
Guo GS; Zhang FM; Gao RJ; Delsite R; Feng ZH; Powell SN
Int J Oral Sci; 2011 Oct; 3(4):176-9. PubMed ID: 22010575
[TBL] [Abstract][Full Text] [Related]
20. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
